EpiCast Report: Epilepsy - Epidemiology Forecast to 2026

  • ID: 4429115
  • Drug Pipelines
  • 45 pages
  • GlobalData
1 of 3
EpiCast Report: Epilepsy - Epidemiology Forecast to 2026

Summary

Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain (WHO, 2017). It is one of the most common neurological conditions globally (WHO, 2017). Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered a seizure and is referred to a specialist, where a description of the symptoms before the seizure and the seizure itself are used for a diagnosis (NHS, 2014).

In the 7MM, the lifetime diagnosed prevalent cases of epilepsy will increase from almost 11 million cases in 2016 to just over 11.5 million cases in 2026, at an Annual Growth Rate (AGR) of almost 0.5% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the lifetime diagnosed prevalent cases of epilepsy will increase from around 4.5 million cases in 2016 to about 4.7 million cases in 2026, at an AGR of close to 0.6%.

In 2016, there were about 5.6 million active diagnosed prevalent cases of epilepsy in the 7MM, which is expected to increase to just over 6 million cases by 2026, at an AGR of around 0.6%. Among the 7MM, the US had the highest number of active diagnosed prevalent cases of epilepsy in 2016 and 2026, at around 3.2 million cases and about 3.5 million cases, respectively. However, France will have the highest growth in the 7MM, at an AGR of over 4%.

The report "EpiCast Report: Epilepsy - Epidemiology Forecast to 2026", provides an overview of the risk factors and the global and historical trends for epilepsy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiology forecast of the lifetime and active diagnosed prevalent cases of epilepsy in these markets from 2016-2026.

Scope
  • The Epilepsy EpiCast Report provides an overview of the risk factors and global trends of epilepsy in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of the lifetime and active diagnosed prevalent cases of epilepsy in these markets from 2016-2026. The lifetime and active diagnosed prevalent cases are segmented by sex and age (ranging from age 0 to ages 80 years and older). The active diagnosed prevalent cases are further segmented by seizure type (generalized, focal, unclassified/unknown) and drug resistance.
  • The epilepsy epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The Epilepsy EpiCast report will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global epilepsy market.
  • Quantify patient populations in the global epilepsy market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for epilepsy therapeutics in each of the markets covered.
  • Understand seizure type and drug resistance in active diagnosed prevalent cases of epilepsy.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents

2 Epilepsy: Executive Summary
2.1 Related Reports
2.2 Upcoming Related Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 US
3.3.2 5EU
3.3.3 Japan
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Epilepsy (2016-2026)
3.5.1 Lifetime Diagnosed Prevalent Cases of Epilepsy
3.5.2 Active Diagnosed Prevalent Cases of Epilepsy
3.5.3 Age-Specific Active Diagnosed Prevalent Cases of Epilepsy
3.5.4 Sex-Specific Active Diagnosed Prevalent Cases of Epilepsy
3.5.5 Active Diagnosed Prevalent Cases by Seizure Type
3.5.6 Drug Resistant Active Diagnosed Prevalent Cases
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

4 Appendix
4.1 Bibliography
4.2 Primary Research - Prescriber Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About
4.5 Contact
4.6 Disclaimer

List of Tables
Table 1: Risk Factors and Comorbidities for Epilepsy
Table 2: 7MM, Lifetime Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, Select Years 2016-2026.
Table 3: 7MM, Active Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, Select Years 2016-2026
Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: 7MM, Lifetime Diagnosed Prevalent Cases of Epilepsy, Both Sexes, All Ages, 2016 and 2026
Figure 2: 7MM, Active Diagnosed Prevalent Cases of Epilepsy, Both Sexes, All Ages, 2016 and 2026
Figure 3: 7MM Age-Standardized Lifetime Diagnosed Prevalence, Men, Women, All Ages, 2016 (%)
Figure 4: 7MM Age-standardized Active Diagnosed Prevalence, Men, Women, All Ages, 2016 (%)
Figure 5: The Sources Used to Calculate the Lifetime Diagnosed Prevalence of Epilepsy
Figure 6: The Sources Used and Not Used in the Forecast for the Active Diagnosed Prevalence
Figure 7: The Sources Used and Not Used in the Forecast for the Seizure Type Distribution of Active Diagnosed Prevalent Cases
Figure 8: The Sources Used in the Forecast for the Drug Resistant Active Diagnosed Prevalent Cases
Figure 9: 7MM, Age-Specific Active Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, 2016
Figure 10: 7MM Sex-Specific Active Diagnosed Prevalent Cases of Epilepsy, All Ages, 2016.
Figure 11: 7MM, Active Diagnosed Prevalent Cases of Epilepsy by Seizure Type, Men and Women, All Ages, 2016
Figure 12: 7MM, Active Diagnosed Prevalent Cases by Response to AED Treatment, Men and Women, All Ages, 2016.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll